Riociguat for the treatment of pulmonary arterial hypertension.
暂无分享,去创建一个
M. Humbert | Z. Jing | H. Ghofrani | F. Grimminger | A. Keogh | E. Grünig | L. Rubin | D. Langleben | M. O. Kilama | N. Galiè | D. Neuser | A. Fritsch
[1] Chen Wang,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.
[2] M. Puhan,et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[3] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[4] H. Palevsky,et al. Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.
[5] W. Seeger,et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats , 2011, BMC Pharmacology.
[6] O. V. Evgenov,et al. Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats , 2011, PloS one.
[7] H. Ghofrani,et al. Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.
[8] Pál Pacher,et al. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. , 2011, Circulation.
[9] J. Stasch,et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.
[10] F. Grimminger,et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study , 2010, European Respiratory Journal.
[11] R. Barst,et al. Clinical worsening in trials of pulmonary arterial hypertension: results and implications , 2010, Current opinion in pulmonary medicine.
[12] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[13] N. Weissmann,et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension , 2009, European Respiratory Journal.
[14] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.
[15] J. Cappelleri,et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. , 2009, Chest.
[16] Jeffrey L. Anderson,et al. ACCF/AHA Expert Conseusus Document , 2009 .
[17] W. Seeger,et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension , 2008, European Respiratory Journal.
[18] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[19] W. Seeger,et al. Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.
[20] M. Pillinger,et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[21] Orris,et al. INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .
[22] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[23] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[24] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.